Current development of chimeric antigen receptor T‐cell therapy for diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma
European Journal of Haematology · 2024
DOI: 10.1111/ejh.14166 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Nobuhiko Yamauchi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T‐cell therapy has become a commercially available treatment option for relapsed or refractory (r/r) diffuse large B‐cell lymphoma (DLBCL) with two or more lines of prior therapies, and recently for high‐risk r/r DLBCL with one prior line of therapy. The successful development of CAR T‐cell therapy for multiple relapsed DLBCL has led to a boom in subsequent trials that investigated its utility in patients with other r/r B‐cell lymphoma subtypes. However, CAR T‐cell therapy is a multistep process that includes leukapheresis and manipulation which take several weeks. Therefore, patients with rapidly progressing or bulky disease may not be able to complete the therapeutic regimen involving CAR T‐cell products. This raises the question of the generalizability of the results of pivotal studies to the entire population. In this review, we summarize the development of CAR‐T cell therapy for B‐cell lymphoma and discuss strategies to further improve the clinical outcomes of this treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.
ORCID-Profile: Dai Maruyama
Zitieren
APA
Yamauchi, N., & Maruyama, D. (2024). Current development of chimeric antigen receptor T‐cell therapy for diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma. European Journal of Haematology. https://doi.org/10.1111/ejh.14166
Vancouver
Yamauchi N, Maruyama D. Current development of chimeric antigen receptor T‐cell therapy for diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma. European Journal of Haematology. 2024. doi:10.1111/ejh.14166
BibTeX
@article{Yamauchi2024,
author = {Yamauchi, Nobuhiko and Maruyama, Dai},
title = {Current development of chimeric antigen receptor T‐cell therapy for diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.14166}
}
EUVIMED